Navigation Links
Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
Date:6/9/2008

CAMBRIDGE, Mass., June 9 /PRNewswire/ -- Radius Health ("Radius") announced today that the company has selected the first lead candidate, RAD140, from its internal nonsteroidal selective androgen receptor modulator ("SARM") discovery program, for full preclinical development as a potential therapy for the treatment of age-related muscle loss (sarcopenia) and other musculoskeletal conditions such as osteoporosis. Radius selected RAD140 from a series of promising SARMs after it demonstrated exceptional selectivity for anabolic activity in well-validated in vivo models. Radius expects to complete formal toxicology studies that will allow the company to commence human clinical trials for RAD140 in the first half of 2009.

"We are highly encouraged by data on RAD140 from our in vivo models, which demonstrate RAD140's strong potential to build new bone and muscle, with significant selectivity over prostate and other non-target tissues, excellent oral availability, and a promising safety profile," said Chris Miller, PhD, Vice President of Chemistry of Radius.

"The selection of RAD140 for pre-IND development is a significant milestone for Radius as it represents the first novel proprietary compound to emerge from the company's internal discovery program," said C. Richard Lyttle, PhD, President and CEO of Radius. "The Radius team has been extremely productive in advancing this first lead SARM candidate, and I am confident in our ability to complete preclinical studies and to initiate expected clinical trials in 2009."

About SARMs

Selective androgen receptor modulators (SARMs) are a novel class of androgen receptor ligands that bind to and selectively activate androgen receptors to promote or inhibit specific androgen action in different tissues. SARMs have the potential to substantially expand the clinical benefits of androgens, including testosterone, on muscle and bone while avoiding the unwanted side-effects, which include stimulation of
'/>"/>

SOURCE Radius Health
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
2. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
7. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
10. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
11. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 Following ... of their transactions, Array BioPharma Inc. (NASDAQ:  ARRY) ... and encorafenib definitive agreements with Novartis.  Along with ... an upfront payment of $85 million from Novartis. ... noted, "With the close of the Novartis-GSK transaction, ...
(Date:3/2/2015)... 2, 2015  The International Myeloma Foundation (IMF), ... myeloma patients while working toward prevention and a ... March to be Myeloma Awareness Month (#MAM). ... Awareness Month in 2009. Throughout the month, the ... community events, social media campaigns, story sharing, and ...
(Date:3/2/2015)... -- Cardinal Health today announced plans to acquire Johnson ... cardiology and endovascular devices, for $1.944 billion in cash, ... of tax benefits. The acquisition is expected to be ... senior unsecured notes and the remainder with existing cash. ... the United States and key non-U.S. countries ...
Breaking Medicine Technology:Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5International Myeloma Foundation Declares March "Myeloma Awareness Month" 2International Myeloma Foundation Declares March "Myeloma Awareness Month" 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 2Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 4Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 5Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 6Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 7
... Dec. 8, 2011  RainTree Oncology Services (RainTree Oncology), ... and management services, today announced it has signed ... the nation,s largest privately-owned specialty pharmacy providing medication ... the Company to provide community oncology practices with ...
... 2011   Leatt Corporation (OTC: LEAT.PK), a global ... brace system designed to help prevent potentially devastating injuries ... today that the 2011 Annual Meeting (Meeting) of its ... Thursday, December 22, 2011.  Stockholders of record as of ...
Cached Medicine Technology:RainTree Oncology Services Announces Service Agreement With Diplomat Specialty Pharmacy 2RainTree Oncology Services Announces Service Agreement With Diplomat Specialty Pharmacy 3Leatt Corporation Announces 2011 Annual Shareholders' Meeting 2
(Date:3/2/2015)... 2015 ZoomCare announced today the ... healthcare. Zoom will expand its Portland on-demand neighborhood ... advanced care studios delivering urgent care, primary care, ... care and outpatient surgery. With its new neighborhood ... all healthcare needs outside of hospitalization. , “2015 ...
(Date:3/2/2015)... York (PRWEB) March 02, 2015 ... at Recovery Unplugged™—will be delivering a plenary address ... Perspective on the Art of Healing and Recovery ... (NCAD) and Behavioral Healthcare Executive Summit (BHES).     , ... Mr. Supa’s songs have been recorded by some ...
(Date:3/2/2015)... March 02, 2015 This year, the National ... and will provide opportunities for people across the country to ... help people with MS live their best lives. MS Awareness ... to inspire others to join the Society’s vision of a ... unpredictable, often disabling disease of the central nervous system, interrupts ...
(Date:3/2/2015)... Regulatory Compliance Associates® Inc. (RCA), ... and technical consulting, announces Mr. Seyed Khorashahi has ... , Before joining RCA, Mr. Khorashahi had over ... all aspects of developing safety-critical medical devices. ... Regulatory Compliance Associates Inc., Baxter Healthcare, and Beckman ...
(Date:3/2/2015)... Many mainstream media outlets have run stories ... how much of that news reporting is true? Many ... measles, but whose youngsters later developed autism, will assemble ... comprised of professionals, clinicians, researchers, therapists, advocates, and others. ... questions about the body and childhood health will have ...
Breaking Medicine News(10 mins):Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Growing List of Professionals Gather for World’s Most Comprehensive Autism Conference in Chicago, May 2015 2
... 18, 2008 TAP Pharmaceutical Products Inc. today reported ... new drug TAK-390MR, the first proton pump inhibitor (PPI) ... patients with erosive esophagitis (EE) and in maintenance of ... Disease Week (DDW) annual meeting in San Diego. , ...
... the 2000 census, Americans office workers spend an average ... work stations. Many recent studies on job satisfaction have ... environments, often under artificial light in windowless offices, report ... can employers make office environments more conducive to productivity ...
... 19 Volcano Corporation,(Nasdaq: VOLC ), a ... Optical Coherence Tomography (OCT) products designed,to enhance the ... said today that it will be participating in ... May 20., The presentation by Scott Huennekens, ...
... and progression of prostate cancer have eluded scientists ... have identified a specific gene expression profile of ... future treatments. The findings, published in BioMed Centrals ... that are differentially expressed in certain prostate cancer ...
... CHICAGO, May 19 SmithAmundsen LLC is pleased,to announce ... Chicago office,has been elected partner, effective May 17, 2008., ... Health Care practice group,focusing her work on health care ... Health Care Agencies, involving,the defense of both nursing and ...
... 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... rejoined the company in a part-time position ... owned subsidiary of Alexza. Mr.,Williams will have ... Singapore and establishing potential joint ventures in,Singapore. ...
Cached Medicine News:Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 4Health News:Greener offices make happier employees 2Health News:Volcano Corporation Presentation at JMP Conference to be Webcast 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:SmithAmundsen Elects New Partner, Linda F. Newman 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3
Inquire...
... - Anatomically designed to enhance the chin contour, ... mandible with a high-profile central chin projection. ... entire mandible, this implant provides a high central ... arms. Cleft Chin Implants - Designed with ...
... IEC CL40 and FL40 Centrifuge Series ... and versatility to increase your productivity ... broad array of rotors and accessories ... microplate applications, the IEC CL40 and ...
... Series offers unsurpassed versatility and exceptional ... liter benchtop centrifuge. With its broad ... high-speed centrifugation capabilities, the IEC CL31 ... to meet a variety of sample ...
Medicine Products: